
Increasing Access to Innovative Medicines
Written Submission for the Pre-Budget Consultations in Advance of the Upcoming Federal Budget
IMC is committed to working with governments and stakeholders to strengthen Canada’s health systems.
IMC relies on trusted data and research to inform our work, and to create useful tools and resources for all stakeholders.
Learn more about IMC, our members, and our commitment to ethics and social responsibility.
Partnering to champion policies that drive the discovery, development and delivery of transformative medicines and vaccines.
New medicines and vaccines save lives and help make our healthcare system more cost‑effective.
Preventing or curing disease means extending lives, relieving suffering and improving people’s quality of life.
Promoting a robust regulatory protocol means ensuring safe and effective medicines for Canadians.
Supporting sustainable healthcare means we all spend more time enjoying life and being productive.
Innovative Medicines Canada members
High-quality Canadian jobs
Total yearly economic impact
Access to Medicine • March 10, 2025
Written Submission for the Pre-Budget Consultations in Advance of the Upcoming Federal Budget
Economic Impact • May 12, 2025
Economic Impact • May 12, 2025
This study examines the contribution of Canada’s research and development (R&D) pharmaceutical sector to the Canadian economy in 2022. It builds upon the annual reports produced since 2018.
Access to Medicine • May 06, 2025
The process for Canadians to access new medicines is extremely complex and involves several different federal, provincial, and territorial agencies. It takes two years following approval (736 days) for Canadian patients to get access to a drug in the public plan, whereas those in the private plan get access to a drug in less than one year (226 days).
Access to Medicine • March 10, 2025
Written Submission for the Pre-Budget Consultations in Advance of the Upcoming Federal Budget
Economic Impact • May 12, 2025
Economic Impact • May 12, 2025
This study examines the contribution of Canada’s research and development (R&D) pharmaceutical sector to the Canadian economy in 2022. It builds upon the annual reports produced since 2018.
Access to Medicine • May 06, 2025
The process for Canadians to access new medicines is extremely complex and involves several different federal, provincial, and territorial agencies. It takes two years following approval (736 days) for Canadian patients to get access to a drug in the public plan, whereas those in the private plan get access to a drug in less than one year (226 days).
Access to Medicine • March 10, 2025
Written Submission for the Pre-Budget Consultations in Advance of the Upcoming Federal Budget
Press Release March 21, 2025
Ottawa, March 21, 2025 – With the imminent announcement of a federal election, Canadians have an opportunity to reflect on the […]
Press Release December 16, 2024
Toronto, December 16, 2024 – Innovative Medicines Canada (IMC) welcomes the collective agreement amongst Canada’s Premiers to take meaningful action […]
Press Release October 03, 2024
“Minister Holland’s recent letter to SOCI regarding the impact of Bill C-64 on private insurance in Canada confirms our concerns: […]
Press Release June 12, 2025
Geneva and Ottawa, June 12 – Ahead of the upcoming G7 Leaders’ Summit, the global pharmaceutical industry, represented by the […]
Press Release May 12, 2025
Innovative Pharmaceutical Industry Contributed $18.4 Billion to the Canadian Economy in 2022 Ottawa, May 12, 2024 – New data released […]
Press Release May 05, 2025
Nominate Trailblazers in Health Equity Ottawa, May 5, 2025 – The Health Research Foundation (HRF) of Innovative Medicines Canada is […]
Press Release April 29, 2025
Ottawa, ON – Innovative Medicines Canada (IMC) congratulates Mark Carney on his election as Canada’s Prime Minister, the Liberal Party […]
Press Release April 01, 2025
Ottawa, April 1, 2025 – Quebec signed a bilateral agreement under the federal government’s National Strategy for Drugs for Rare […]
Press Release March 21, 2025
Ottawa, March 21, 2025 – With the imminent announcement of a federal election, Canadians have an opportunity to reflect on the […]
Press Release December 16, 2024
Toronto, December 16, 2024 – Innovative Medicines Canada (IMC) welcomes the collective agreement amongst Canada’s Premiers to take meaningful action […]
Press Release October 03, 2024
“Minister Holland’s recent letter to SOCI regarding the impact of Bill C-64 on private insurance in Canada confirms our concerns: […]
Press Release June 12, 2025
Geneva and Ottawa, June 12 – Ahead of the upcoming G7 Leaders’ Summit, the global pharmaceutical industry, represented by the […]
Press Release May 12, 2025
Innovative Pharmaceutical Industry Contributed $18.4 Billion to the Canadian Economy in 2022 Ottawa, May 12, 2024 – New data released […]
Press Release May 05, 2025
Nominate Trailblazers in Health Equity Ottawa, May 5, 2025 – The Health Research Foundation (HRF) of Innovative Medicines Canada is […]
Press Release April 29, 2025
Ottawa, ON – Innovative Medicines Canada (IMC) congratulates Mark Carney on his election as Canada’s Prime Minister, the Liberal Party […]
Press Release April 01, 2025
Ottawa, April 1, 2025 – Quebec signed a bilateral agreement under the federal government’s National Strategy for Drugs for Rare […]
Press Release March 21, 2025
Ottawa, March 21, 2025 – With the imminent announcement of a federal election, Canadians have an opportunity to reflect on the […]
Press Release December 16, 2024
Toronto, December 16, 2024 – Innovative Medicines Canada (IMC) welcomes the collective agreement amongst Canada’s Premiers to take meaningful action […]
Press Release October 03, 2024
“Minister Holland’s recent letter to SOCI regarding the impact of Bill C-64 on private insurance in Canada confirms our concerns: […]
Informative content to keep you up to date on the most pressing issues facing our industry.